Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Infanrix Hexa er større end risiciene til primær - og boostervaccination af børn mod difteri, tetanus, pertussis, hepatitis B, poliomyelitis og sygdom forårsaget af Hib.
The Committee for Medicinal Products for Human Use (CHMP) decided that Infanrix Hexa’ s benefits are greater than its risks for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Hib.